palivizumab [aapp, imft, phsu]
prophylaxis [inpr]
Respiratory syncytial virus [virs]
Disease [dsyn]
Result [ftcn]
Four [qnco]
palivizumab [aapp, imft, phsu]
Usage [ftcn]
objectives [inpr]
Food and Drug Administration [hcro]
Approved [qlco]
palivizumab [aapp, imft, phsu]
Synagis [aapp, imft, phsu]
Prevention [topp]
Severe [qlco]
Lower respiratory tract infection [dsyn]
secondary [neop]
Respiratory syncytial virus [virs]
paediatric [bmod]
Patients [podg]
High Risk [qlco]
Disease [dsyn]
Required hospitalization [fndg]
Immediate [tmco]
Approval [qlco]
Two [qnco]
retrospective [resa]
reviews [inpr]
Conduct [inbe]
Medical Records [inpr]
Patients [podg]
Received [qlco]
Dose [qnco]
palivizumab [aapp, imft, phsu]
Respiratory syncytial virus [virs]
Seasons [tmco]
Analysis [lbpr]
Data [idcn]
Rate [acty]
Respiratory syncytial virus [virs]
Hospitalization [hlca]
Length [qnco]
Hospital Stay [tmco]
intensive care unit [hcro, mnob]
admission [hlca]
Compliance [qnco]
palivizumab [aapp, imft, phsu]
Administration [ocac]
Two [qnco]
prospective [resa]
Multicenter Trials [resa]
Registry [inpr]
Respiratory syncytial virus [virs]
Seasons [tmco]
Registries [inpr]
Characterized [acty]
Demographics [idcn]
Outcome [ftcn]
High risk infant [fndg]
Children [aggp]
Received [qlco]
prophylaxis [inpr]
Respiratory syncytial virus [virs]
risk factors [qnco]
Respiratory syncytial virus [virs]
Hospitalization [hlca]
Patterns [spco]
Scope [cnce]
palivizumab [aapp, imft, phsu]
Usage [ftcn]
Health Care [hlca]
Sites [spco]
palivizumab [aapp, imft, phsu]
First [qnco]
Season [tmco]
General [spco]
Nine [qnco]
Study [mnob]
Sites [spco]
Engaged [fndg]
retrospective [resa]
Chart review [hlca]
Infants [aggp]
Children [aggp]
Gestational Age [orga]
Equal [qlco]
weeks [tmco]
chronology [inpr]
Age [orga]
Time [tmco]
First [qnco]
palivizumab [aapp, imft, phsu]
injection [topp]
Received [qlco]
One [qnco]
Dose [qnco]
Children [aggp]
Evaluable [dsyn]
Data [idcn]
Only [qnco]
hospitalized [fndg]
confirmed [qlco]
Respiratory syncytial virus [virs]
Disease [dsyn]
admitted [hlca]
confirmed [qlco]
Gestational Age [orga]
Premature [tmco]
majority [socb]
weeks [tmco]
Gestational Age [orga]
WGA [mbrt]
WGA [mbrt]
palivizumab [aapp, imft, phsu]
Second [qnco]
Season [tmco]
General [spco]
Respiratory syncytial virus [virs]
Season [tmco]
Hospitals [hcro, mnob]
University Medical Centers [hcro, mnob]
Represent [acty]
Cross-section [spco]
Health care facilities [hcro, mnob]
Contribute [acty]
Second [qnco]
palivizumab [aapp, imft, phsu]
Study [mnob]
Group [idcn]
Sites [spco]
Collected [idcn]
retrospective [resa]
Data [idcn]
Charts [inpr]
Children [aggp]
Received [qlco]
injection [topp]
palivizumab [aapp, imft, phsu]
Analysis [lbpr]
Medical Records [inpr]
Revealed [qlco]
admission [hlca]
Rate [acty]
confirmed [qlco]
Respiratory syncytial virus infection [dsyn]
Consistent [idcn]
Overall [inpr]
Hospitalization [hlca]
Rate [acty]
Previous [tmco]
Season [tmco]
palivizumab [aapp, imft, phsu]
Outcome [ftcn]
Registry [inpr]
Three [qnco]
Sites [spco]
Represent [acty]
paediatric [bmod]
offices [mnob]
Clinics, Free-Standing [hcro]
Hospital clinic [hcro, mnob]
Based [ftcn]
prospective [resa]
Observational Study [resa]
Evaluate [ftcn]
Scope [cnce]
palivizumab [aapp, imft, phsu]
Usage [ftcn]
Cross-section [spco]
Infants [aggp]
centers [spco]
Collected [idcn]
Outcome [ftcn]
Data [idcn]
Respiratory syncytial virus [virs]
hospital admissions [hlca]
injection [topp]
History [ocdi]
Adherence [ftcn]
palivizumab [aapp, imft, phsu]
Administration [ocac]
Protocol [inpr]
Infants [aggp]
Bear [mamm]
weeks gestation [fndg]
Patients [podg]
weeks [tmco]
Gestational Age [orga]
account [idcn]
Approximately [qlco]
Gestational Age [orga]
weeks [tmco]
Subject [grup]
Available [ftcn]
Follow-up [fndg]
Data [idcn]
Overall [inpr]
confirmed [qlco]
Respiratory syncytial virus [virs]
Hospitalization [hlca]
Rate [acty]
palivizumab [aapp, imft, phsu]
Outcome [ftcn]
Registry [inpr]
Health center [hcro, mnob]
Care [acty]
Infants [aggp]
Second [qnco]
prospective [resa]
palivizumab [aapp, imft, phsu]
Outcome [ftcn]
Registry [inpr]
Primary [qlco]
Outcome [ftcn]
Study [mnob]
Measured [qlco]
occurrence [ftcn]
Respiratory syncytial virus [virs]
Hospitalization [hlca]
secondary [neop]
variables [qlco]
risk factors [qnco]
Respiratory syncytial virus bronchiolitis [dsyn]
Compliance [qnco]
Projected [inpr]
palivizumab [aapp, imft, phsu]
injections [topp]
Based [ftcn]
month [tmco]
Initial [tmco]
Dose [qnco]
Nine [qnco]
Percent [qnco]
N NOS [aapp, imft]
Infants [aggp]
Bear [mamm]
weeks [tmco]
Gestational Age [orga]
N NOS [aapp, imft]
Bear [mamm]
Gestational Age [orga]
weeks [tmco]
N NOS [aapp, imft]
Bear [mamm]
weeks [tmco]
Gestational Age [orga]
Percent [qnco]
N NOS [aapp, imft]
Children [aggp]
Sufficient [qlco]
Risk [qlco]
palivizumab [aapp, imft, phsu]
prophylaxis [inpr]
Second [qnco]
Season [tmco]
Six [qnco]
Subject [grup]
experience [menp]
Respiratory syncytial virus [virs]
hospital admissions [hlca]
Overall [inpr]
Hospitalization [hlca]
Rate [acty]
Four [qnco]
retrospective [resa]
prospective [resa]
Data [idcn]
palivizumab [aapp, imft, phsu]
Clinical [qlco]
practice [menp]
Wealthy [qlco]
Real [qlco]
Life [idcn]
Information [idcn]
Clinical [qlco]
Effectiveness [qlco]
Respiratory syncytial virus [virs]
immunoprophylaxis [topp]
Large [qnco]
Cohort [popg]
High risk infant [fndg]
Diverse [qlco]
paediatric [bmod]
offices [mnob]
clinics [hcro, mnob]
United States [geoa]
